Expect near-term selling pressure as the offering prices at only a 2% discount to market. Monitor for any further capital needs or clinical trial updates that could shift sentiment. The Phase 3 Alzheimer's readout remains the key catalyst, but the financing overhang may persist until data emerges.
Price Chart
Executive Summary
Annovis Bio is raising approximately $13.8M in net proceeds through a dilutive offering of 7.9M shares and warrants, priced at $1.90/unit (vs. last sale $1.94). The company has a going concern warning with only $14.2M cash (as of Mar 31, 2026) and an accumulated deficit of $181.3M. This capital raise, following a poor Q1 earnings report, underscores acute funding needs and dilutes existing shareholders by ~23% (excluding warrants). Traders should expect near-term price pressure given the minimal premium to market and ongoing cash burn.
Key Facts
- Offering 7,895,000 shares of common stock plus warrants to purchase up to 7,105,500 shares at $2.25 exercise price, 6-year term
- Combined offering price $1.90 per unit, net proceeds ~$13.8M
- Cash and cash equivalents of $14.2M as of March 31, 2026; company believes runway only extends to Q4 2026
- Going concern warning from independent auditor; accumulated deficit of $181.3M
- Q1 2026 earnings (filed May 15) showed increased net loss and cash burn
Financial Impact
Dilution of ~23% to existing shareholders from the common stock offering (plus additional dilution from warrants if exercised). Net proceeds of $13.8M will extend cash runway modestly but do not resolve the structural funding shortfall.
Risk Factors
- Immediate dilution and potential further offerings due to insufficient cash runway
- Clinical trial failure or delay of pivotal Phase 3 AD data
- Going concern risk if additional capital is not raised
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-064510 |
| Document: 0001104659-26-064510-index-headers.html | 0001104659-26-064510 |
| Document: 0001104659-26-064510-index.html | 0001104659-26-064510 |
| Document: 0001104659-26-064510.txt | 0001104659-26-064510 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 10, 2026 12w ago | 8-K | $1.86 $1.88 | ▲ +1.08% | ▼ −1.35% | $1.18 (−36.56%) |
May 20, 2026 19w ago | 424B5 | $2.15 $1.73 | ▲ +19.53% | ▲ +19.87% | $1.18 (+45.12%) |
May 19, 2026 19w ago | 424B5 | $2.04 $1.75 | ▲ +14.22% | ▲ +14.96% | $1.18 (+42.16%) |
May 15, 2026 20w ago | 8-K | $2.05 $1.79 | ▼ −12.68% | ▼ −14.26% | $1.18 (−42.44%) |
May 15, 2026 20w ago | Press Release | $2.06 $1.78 | ▲ +13.59% | ▲ +15.71% | $1.18 (+42.72%) |
Apr 10, 2026 25w ago | Press Release | $1.59 $2.26 | ▲ +42.14% | ▲ +33.61% | $1.18 (−25.79%) |
Mar 19, 2026 28w ago | Press Release | $2.67 $1.87 | ▼ −29.96% | ▼ −37.58% | $1.18 (−55.81%) |
Mar 16, 2026 28w ago | Press Release | $2.83 $1.73 | ▼ −38.87% | ▼ −42.65% | $1.18 (−58.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access